July 23, 2021 - … Biogen to Present Data from ADUHELM and Alzheimer’s Disease Portfolio at 2021 Alzheimer’s … International Conference … Biogen to Present Data from ADUHELM and Alzheimer’s Disease Portfolio at 2021 Alzheimer’s … International Conference Biogen to Present Data from ADUHELM and Alzheimer’s Disease Portfolio at 2021 Alzheimer’s …
June 7, 2021 - … to help patients with Alzheimer’s disease access ADUHELM™ … Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM™ Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM™ June 7, 2021 News Release General Programs now …
March 16, 2022 - … Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of … for More Than Two Years … Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of … for More Than Two Years Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of …
December 16, 2021 - … Update on the Phase 4 Confirmatory Study of ADUHELM® … Update on the Phase 4 Confirmatory Study of ADUHELM® Update on the Phase 4 Confirmatory Study of ADUHELM® December 16, 2021 News Release General CAMBRIDGE, …
December 22, 2021 - … aducanumab to patients in Japan expeditiously. About ADUHELM ® (aducanumab-avwa) injection 100 mg/mL solution for intravenous use In the United States, ADUHELM is indicated for the treatment of Alzheimer’s disease. Treatment with ADUHELM should be initiated in patients with mild cognitive …
December 20, 2021 - … Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early … Alzheimer’s Disease … Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early … Alzheimer’s Disease Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early …
April 7, 2022 - … effectively denies all Medicare beneficiaries access to ADUHELM ® (aducanumab-avwa), the first and only FDA-approved … continuity of care for Medicare beneficiaries already on ADUHELM. Biogen is carefully considering its options and … evaluates the business impact of this decision. About ADUHELM ® (aducanumab-avwa) injection 100 mg/mL for …
January 11, 2022 - … denies nearly all Medicare beneficiaries from accessing ADUHELM® (aducanumab-avwa) 100 mg/mL injection for … approval was supported by clinical data showing that ADUHELM impacted the underlying pathology of Alzheimer’s … screening for its post-marketing confirmatory study for ADUHELM® (aducanumab-avwa) in May 2022, with a primary …
December 17, 2021 - … Drug Administration (FDA) granted accelerated approval for ADUHELM ® (aducanumab-avwa) 100 mg/mL injection for … the disease by reducing amyloid beta plaques in the brain. ADUHELM is also approved in the United Arab Emirates (UAE). About ADUHELM ® (aducanumab-avwa) injection 100 mg/mL solution for …
November 11, 2021 - … New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in … … New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in … Disease New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in …